Fresenius Medical Care -- How the Business Works

The Fresenius Medical Care Business Model

Duopoly dynamics: FMS and DaVita together control ~75-80% of US outpatient dialysis. Barriers to entry are enormous: regulatory licensing, nephrologist recruitment, Medicare reimbursement expertise, and capital intensity. Studies show monopoly/duopoly dialysis markets carry $495+ higher average commercial prices per patient. Independent share has shrunk from 20.4% (2005) to ~10.6% today. FMS is uniquely vertically integrated -- it manufactures the machines and consumables used in its own clinics and sells to third-party providers, creating a dual revenue stream no competitor can fully replicate.

Revenue by Segment -- FY2025 (~EUR 19.5B)

Growth Vectors and Timeline to Materiality

FME25 Program Delivery -- Savings vs Target

1. US dialysis duopoly with shrinking independent share. FMS (~38%) and DaVita (~37%) together control ~75-80% of US outpatient dialysis. Independent operators have shrunk from 20.4% (2005) to ~10.6% today. Barriers to entry are enormous: regulatory licensing requirements, nephrologist recruitment pipelines, Medicare reimbursement expertise, and significant upfront capital. New entrants face a market where two incumbents have decades of scale advantages and payer relationships.

2. Vertical integration -- only player manufacturing + delivering. FMS is uniquely positioned as both the #1 dialysis products manufacturer and the #1 dialysis services provider globally. It makes the machines (including the new 5008X), dialyzers, and concentrates used in its own ~4,000 clinics -- and sells them to third-party providers including competitors. This creates a dual revenue stream and cost advantage that no other company can fully replicate. DaVita, by contrast, is a pure services company that must purchase equipment from third parties.

3. Recurring treatment revenue with life-sustaining necessity. Dialysis patients require treatment 3 times per week to survive -- this is not elective care. Once a patient starts at an FMS clinic, switching costs are high (physician relationships, proximity, familiarity). Revenue per patient is highly predictable and recurring, creating a base of annuity-like cash flows. ~550K Americans are on dialysis with minimal churn outside of mortality or transplant.

4. Global scale with no peer. With ~4,000 clinics across 34 countries, FMS has a global footprint that no competitor approaches. DaVita is primarily US-focused. This gives FMS purchasing leverage on supplies, ability to allocate capital across geographies, and a platform to roll out innovations (like HVHDF) globally once proven in lead markets.

5. 5008X/HVHDF innovation leadership. The 5008X machine enabling high-volume hemodiafiltration is a genuinely differentiated clinical advance (23% mortality reduction in the CONVINCE trial). FMS manufactured the machine in-house and is rolling it out exclusively through its own clinic network first, creating a temporary competitive advantage vs DaVita and independents who must wait for third-party HVHDF access.

US volume growth flat for 3 years: The most critical metric -- US same-market treatment growth -- has been near zero for three years. Patient count is down ~15% since 2021. Contributing factors include elevated mortality (flu-related carryover), elevated missed treatments, and structural factors. Management guides flat SMTG for 2026, targeting normalization to 2%+ "once mortality normalizes." Until this inflects, the revenue story is entirely margin-driven.

TDAPA phase-out creates EUR 150-200M headwind: EUR 310M in temporary add-on payments (phosphate binders + catheter lock) boosted 2025 revenue. This TDAPA tailwind phases out in 2026, creating a EUR 150-200M headwind that is the primary reason 2026 operating income is guided flat despite ongoing FME25+ savings (EUR 250M incremental). This makes 2026 a "transition year" that could frustrate investors expecting linear improvement.

Home dialysis structural shift: Home dialysis is growing at ~10% CAGR, faster than in-center. US policy mandates target 30% home dialysis penetration, and "PD-first" policies are spreading globally. FMS generates ~75% of revenue from in-center clinics. While FMS benefits on the products side (it sells PD equipment), an accelerating shift to home dialysis would structurally challenge the core clinic-based business model.

GLP-1 long-tail demand uncertainty: While GLP-1s appear net neutral near-term (they delay but do not prevent dialysis), the long-term impact remains genuinely uncertain. If GLP-1 adoption reaches critical mass and meaningfully slows CKD progression at a population level, the incidence rate of new dialysis patients could decline by 2030+. This tail risk keeps a permanent discount on dialysis equities.

Heavy regulatory/reimbursement dependence: Medicare sets the base reimbursement rate for US dialysis. FMS has limited pricing power -- revenue per treatment is largely policy-determined. ACA subsidy expiry risk could add ~EUR 50M headwind if subsidies lapse. Any adverse Medicare rate changes would flow directly to margins with limited offset options. China regulatory headwinds (~7-10% of Care Enablement revenue) add geographic concentration risk.